New Scleroderma-related findings have linked two variations of the disease, which in turn could lead to effective, new biomarkers and targeted treatments for patients. Two clinically different diseases, localized scleroderma (LS) and systemic sclerosis (SSc), can be characterized by similar T-cell produced cytokines and chemokines in pediatric patients,…
A group from Massachusetts General Hospital is placing possible blame for systemic sclerosis (SSc) pathogenesis on autotaxin (ATX), an enzyme involved in the production of the lipid signaling molecule lysophophatidic acid (LPA). Dr. Falvia V. Castelino, a researcher in the Rheumatology Department, presented the group’s work, “…
Federal University of São Paulo recently initiated a phase 3 clinical trial evaluating the use of probiotics in patients with systemic sclerosis (SSc) to determine the efficacy and safety of treating gastrointestinal symptoms of SSc. As an autoimmune disease, SSc may benefit from probiotics due to their ability to…
The Chief Executive Officer of emerging growth drug development company Corbus Pharmaceuticals Holdings, Inc. has been invited to present at the Virtual Investor Conferences, a live and interactive online event that will take place on Thursday, December 4 at 11:30 a.m. EST. Yuval Cohen, Ph.D., CEO of Corbus,…
At times, a major roadblock to conducting clinical trials is enrolling enough patients to fill a study for appropriate data analyses. This may not be the case for studies involving patients with juvenile localized scleroderma (jLS), according to a study from Hackensack University Medical Center. The study, led by…
Researchers at the Centre for Rheumatology and Connective Tissue Disease at University College London have found new evidence that could help in understanding how lung blood vessel disease (pulmonary vasculopathy) in systemic sclerosis develops. The study could form the basis for future treatments that block the condition from occurring. The work…
Recently, autologous haematopoietic stem cell transplantation (AHSCT) has become more popular in treating patients with systemic sclerosis (SSc). Canadian SSc patients have actually been seeking out experimental AHSCT treatments in the United States to aid their…
Closely examining the capillaries of the fingers, perhaps one of the most non-invasive procedures possible, may be provide insight into pulmonary function in patients with systemic sclerosis (SSc). A research group from Spain, led by Drs. Ivan Castellvi and Jordi Casademont, identified worse forced vital capacity (FVC) and diffusing capacity…
New research presented at the American College of Rheumatology Annual Meeting in Boston highlights that patients with systemic sclerosis with end-stage lung disease cannot be denied lung transplantation on the premises that other extra-pulmonary factors will determine their long-term survival. Scleroderma, also known as systemic sclerosis (SSc), is an autoimmune disease…
Those in the Scleroderma community are taking note of recent news that Bayer HealthCare will be initiating a randomized, double-blind, placebo-controlled, Phase II clinical study to investigate efficacy and safety of riociguat in patients suffering from diffuse cutaneous systemic sclerosis (dcSSc), according to an announcement by the company. The study is…
Get regular updates to your inbox.